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A microplate chemiluminescence enzyme immunoassay (CLEIA) with high sensitivity, selectivity and repro-
ducibility was developed for the determination of free thyroxine (FT4) in human serum. A competitive assay has 
been utilized with horseradish peroxidase (HRP) labeled thyroxine analog in the chemiluminescence (CL) detec-
tion. The CL signal produced by the emission of photons from luminol was directly proportional to the amount 
of analyte. The linear range was 0.45-7.5 ng dL-1 and the detection limit was 0.09 ng dL-1. Experimental condi-
tions, such as temperature, pH, incubation time, titration level and other relevant variables upon the CL signal 
have been examined and optimized. A coefficient of variance of less than 16% was obtained for intra- and in-
ter-assay precision. The present method has been successfully applied to the analysis of FT4 in human serum. 
The positive and negative coincidence ratios are satisfactory. Good correlations were obtained between the re-
sults by the proposed method and radioimmunoassay (RIA), as well as a Bayer ACS-180SE detection system. 
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1.  Introduction 
Thyroxine (3,5,3',5'-tetraiodothyronine, T4) is an 
important hormone secreted by the thyroid gland. It 
has a molecular mass of 777 Dalton and is involved in 
regulating many biological functions, such as oxygen 
consumption, growth, development and protein syn-
thesis. More than 99.9% of the T4 in blood is bound to 
carrier proteins, specially to thyroxine-binding globu-
lin (TBG), and the free fraction of T4 (free T4, FT4) just 
accounts for ～0.03% [1]. But the FT4 represents the 
biologically active form of t h i s  c o m p o u n d .  I t  i s  b e -
lieved that FT4 could cross cell membranes and inter-
acts with receptors [2], showing metabolically active 
and clinically relevant effect. Therefore, measurement 
of FT4 is of value in assessing thyroid function.   
Various methods have been employed to the de-
termination of FT4 in serum, such as equilibrium di-
alysis [3-7], ultrafiltration [8], chromatography on 
polyacrylamide gel [9, 10] or Sephadex [11] , radio-
immunoassay (RIA) by use of the radioactive isotope 
125I [12-14], enzyme immunoassay [15-17], 
time-resolved fluorescence [18], bioluminescent im-
munoassay [19], fluoroimmunoassay [20-23], 
chemiluminescence immunoassay [24, 25], electro-
chemiluminescence immunoassay [26, 27], and mass 
spectrometry [28, 29]. These methods have disadvan-
tages. Direct methods are complex and time consum-
ing. RIA uses radioactive labels and is harmful to the 
operators. ELISA has low sensitivity. Immunoassay 
with chromatography needs a lengthy procedure of 
column preparation and expensive instrumentation. 
Electrochemical method requires preparation of 
working electrodes and complicated operation. 
Chemiluminesence enzyme immunoassay 
(CLEIA)  has high sensitivity and specificity. It has 
been widely used in clinical and biomedical researches 
due to such advantages as no radioactive waste, rela-
tively simple and inexpensive instrumentation, low 
detection limit and wide dynamic range. Generally, 
chemiluminesence detection techniques use horserad-
ish peroxidase (HRP) or alkaline phosphatases (ALP) 
as label for enzyme immunoassay. These enzymes are 
labeled to the antibody or antigen molecules. The 
chemiluminesence substrates undergo a peroxi-
dase-catalyzed oxidation in the presence of a suitable 
oxidant. After the immunological reaction, the 
chemiluminesence intensity of the label is detected for 
the quantitative analysis of antibody or antigen. In this 
paper, a chemiluminesence enzyme immunoassay for 
the determination of FT4 is proposed. FT4 presenting 
in a patient’s serum competes with enzyme-T4 analog 
conjugate for anti-T4 antibodies attached to a solid 
phase. The amount of enzyme-T4 analog conjugate 
binding to the solid phase varies inversely with the 
concentration of FT4 in the serum, constituting the Int. J. Biol. Sci. 2007, 3 
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estimation of FT4 concentration in the serum. The 
competitive reaction principle is shown in Figure 1. It 
is based on the HRP-T4 analog conjugate and the 
chemiluminesence reaction between the enzyme sub-
strate of luminol and hydrogen peroxide. 
 
Figure 1. Principle of the chemiluminescence enzyme 
 
2.  Material and Methods 
Chemicals  
T4 standard was obtained from Sigma (St. Louis, 
USA). Goat anti-T4 polyclonal antibody was pur-
chased from Si Chuan Zheng Long Company (Si 
Chuan, China). HRP-T4 analog conjugate was ob-
tained from BAHT Co., Ltd. (Beijing Atom High Tech 
Co., China). Human sera samples were purchased 
from Beijing 301 Hospital (Beijing, China). The coating 
buffer is citrate acid (0.06 mol L-1, pH 4.8). The block-
ing solution was 0.02 mol L-1 phosphate buffer con-
taining 1% (w/v) BSA and 5% glucose, pH 7.4. The 
washing solution was 0.01 mol L-1 Tris-HCl buffer 
containing 0.05% Tween-20, pH 7.5. Dilution solution 
for HRP-labeled T4 analog was Tris-HCl buffer, pH 
6.5. The chemiluminescence substrate were luminol in 
0.1 mol L-1 Tris-HCl of pH 8.5 and H2O2 in citrate 
buffer of pH 4.5. 
Apparatus 
A chemiluminescence microplate reader 
(BHP9504 from Hamamatsu Co., China) was used. A 
microplate mixer (WZ-2A, Beijing Haidian Medical 
Instrument Factory, Beijing, China) was employed to 
blend the solutions in microwells. The incubation 
procedures were carried out using constant tempera-
ture incubator (PYX-DHS, Shanghai Medical Instru-
ment Factory, Shanghai, China). An automatic plate 
washer was used to wash the microplates (DEM-III, 
Tuopu Analysis Instrument Company, Beijing, China).   
Immunoassay procedure 
Immunoassay procedures were presented in 
Figure 2 [30]. The microplates were coated with 100 
μL of T4 antibody (2.5 μg mL-1) each well in citrate 
buffer (pH 4.8). The plates were allowed to stand 
sealed at 4 ℃ overnight. Then, the plates were de-
canted (tapped and blotted) and post-coated with 300 
μL blocking buffer for 1 h at 37  ℃. The blocking solu-
tion was discarded before assay. In each reaction, 50 
μL T4 standard solutions or serum samples and 100 
μL diluted HRP-T4 analog conjugate were added and 
incubated for 45 min at 37 ℃. After the competitive 
reaction, the plates were washed five times and 100 μL 
chemiluminescence substrate solution was added, and 
the emitted photons were measured. 
 
Figure 2. Schematic of chemiluminescence enzyme immu-
noassay procedures 
Data analysis 
Standards and samples were run in double wells, 
and mean chemiluminescence intensity values were 
used. Standard curves were obtained by plotting 
chemiluminescence intensity against the logarithm of 
analyte concentration. It was fit to the equation of 
logitY-logx, in which the value of logitY was calcu-Int. J. Biol. Sci. 2007, 3 
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lated according to the following formula:   
LogitY = ln
0
0
/ 1
/
B B
B B
−
 
B- CL intensity of FT4 standard or sample 
B0- CL intensity of zero standard 
3.  Results and Discussion 
Physicochemical parameter optimization 
Effects of temperature and pH 
The equilibrium between bound T4 and FT4 is 
dependent on the temperature. It has been shown that 
when the temperature increases from 20 ℃ to 37 ℃, 
the concentration of FT4 is doubled [31]. pH seems to 
influence the equilibrium between the bound T4 and 
the FT4 too [32-34]. The immunoassay reaction was 
performed at 37 ℃ and room temperature, respec-
tively. At 37℃, the detection limit was lower and the R 
(linear correlation coefficient) was higher than those at 
room temperature. Thus 37 ℃ incubation time was 
used. The effects of pH on the assay performance on 
the assay performance parameters, including R, 
RLUmax (maximal relative light unit), IC50 (the T4 
concentration causing 50% inhibition of RLUmax), 
RLUmax/IC50 was also studied (Table 1). It showed 
that IC50 value reached a maximum and the correla-
tion coefficient was better at pH 6.5. Thus pH 6.5 was 
chosen. 
Table 1. Effect of pH on the immunoassay 
pH 6.5  7.5  8.5 
R 0.9984  0.9904  0.9898 
RLUmax 40140  45759  48862 
IC50 0.66  0.54  0.52 
RLUmax/IC50 60818  84738  93965 
Effect of Tween-20 
Surfactants were commonly used in ELISA to 
reduce nonspecific interaction. The influence of 
Tween-20 on assay performance was examined and 
the results were shown in Table 2. Tweeen-20 could 
interfere with the active sites of reactant molecules 
which had an impact on the CL signal [35]. The RLU is 
so high in the absence of Tween-20 that the sample 
with low, medium, and high concentration can not be 
distinguished. In the presence of 0.05% Tween-20, the 
three samples could be distinguished well. Therefore, 
0.05% Tween-20 was selected. 
Effect of Inhibitors 
Adding analyte analog to the sample could in-
fluence the equilibrium between the free and pro-
tein-bound fractions of T4, bringing bad assay repro-
ducibility. Thus inhibitors of sodium salicylate and 
sodium trichloroacetate were tested. Samples with low, 
medium, and high concentration were chosen to 
evaluate the effect of the inhibitors. Compared with 
sodium trichloroacetate, the correlation coefficient was 
better and stable, and the low and high sample con-
centration could be distinguished well in the presence 
of 0.01% sodium salicylate, thus 0.01% sodium salicy-
late was selected in the subsequent work. The results 
were shown in Table 3.   
Table 2. Effect of Tween-20 on immunoassay RLU and 
sample determination 
performance parameters  without 
Tween-20 
0.05 % Tween-20
S0 1107747  232260 
S1 705427  102804 
S2 536491  56047 
S3 305467  17510 
RLU 
S4 240786  11549 
low N/A  2.73 
medium N/A 3.78 
sample 
concentration 
(ng dL-1)  high N/A  6.25 
R 0.9996  0.9995 
Table 3. Optimization of inhibitors on the immunoassay 
FT4 determined (ng dL-1)  Inhibitors (g mL-1) R 
U1 U 2 U 3 
1.0×10-3 0.9956 N/A 0.68 1.22 
3.0×10-4 0.9989 N/A 1.32 2.09 
1.0×10-4 0.9993 0.35  3.40 1.79 
1.0×10-5 0.9992 0.60  3.74 1.62 
C7H5NaO3 
1.0×10-6 0.9942 0.67  1.62 1.69 
1.0×10-2 0.9596 0.62  0.55 2.27 
5.0×10-3 0.9905 0.44  0.95 2.50 
2.50×10-3 0.9762  0.91  1.80  3.22 
5.0×10-4 0.9605 1.10  2.40 5.15 
2.0×10-4 0.9641 1.13  3.16 5.00 
1.0×10-4 0.9732 0.99  3.35 5.60 
4.0×10-5 0.9927 0.86  2.50 1.23 
4.0×10-6 0.9972 0.95  2.43 1.31 
CCl3COONa
4.0×10-7 0.9991 0.96  2.75 1.49 
Titration level of HRP labeled T4 analog 
Titer levels of labeled T4 analog were determined. 
Upon every dilution we monitored the RLU of T4 
standard. When the titration was higher than 1:500, 
the sensitivity was not satisfied. While the titration 
was lower than 1:2000, the signal was decreased rap-
idly. The results were shown in Fig. 3. Therefore, titra-
tion level of 1:500 was set.   
 
Figure 3. Titration curves of HRP-T4 analog conjugate 
 
Effect of incubation time 
In a competitive ELISA, the interact time between 
immunoreagents may have a direct effect on the sensi-
tivity of the immunoassay [36]. We varied the incuba-Int. J. Biol. Sci. 2007, 3 
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tion time from 15, 30, 45, 60, 90 to 120 min, and as-
sessed the variations of RLUmax and RLUmax/IC50. Re-
sults were shown in Figure 4. The RLUmax increased 
with longer incubation time in the range of 15~120min. 
After 90min, the RLUmax did not change evidently. 
This means the immunoassay reached an equilibrium. 
RLUmax/IC50 ratio reached a maximal value at incuba-
tion time of 90 min. In order to achieve an appropriate 
sensitivity suitable for clinical application, an incuba-
tion time of 45min was set.   
 
Figure 4. Influence of the length of the competitive step on 
immunoassay 
Calibration and sensitivity 
Under the optimal conditions, the standard curve 
obtained with the chemiluminescence detection of 
enzyme activity was presented in Fig. 5. The linear 
rang was 0.45-7.5 ng dL-1. The sensitivity, defined as 
the minimal does that can be distinguished from zero, 
the minimum detected concentration (mean-2S.D. of 
zero standard, 10 replicates) of FT4 was 0.09 ng dL-1.  
 
Figure 5. Calibration graph of microplate chemilumines-
cence enzyme immunoassay for FT4 
Precision  
The intra- and inter-assay precisions, calculated 
by measuring FT4 concentration in three different 
samples, were performed. Good precisions were ob-
tained. The intra- and inter-assay coefficients of varia-
tion (CV) varied from 5.3 to 15.6%. 
Specificity 
Effect of disrupting compounds 
The specificity of the immunoassay was de-
pendent on the antibody’s specificity [37]. The 
cross-reactivity of the anti-T4 antibody was evaluated 
using several T4 disrupting compounds. 
3,5,3'-triiodothyronine (T3) and 3,3',5'-triiodothyronine 
(reverse T3, rT3) were the structurally related com-
pounds of T4 (Figure 7) and were tested in this work. 
The cross-reactivity was calculated by deriving a ratio 
between does of interfering substance to does of thy-
roxine needed to displace the same amount of the 
conjugate. The results were shown in Table 4. The an-
tibody exhibited cross-reactivity all less than 0.01%. 
Therefore, effects of T3 and rT3 in serum on FT4 de-
termination could be neglected. 
Table 4. Cross-reactivity for FT4 in the present assay 
cross-reactive 
substance 
cross-reactive 
substance added 
(ng mL-1) 
FT4 
deter-
mined 
(ng dL-1) 
Cross-reactivity 
(%) 
rT3 0.8  0.01  0.001 
FT3 25  0.26  0.010 
Interferences 
Amount of the interfering substances were added 
to a serum matrix. The effects of some potential inter-
ferences on the determination were shown in Table 5. 
Sodium citrate and heparin enhanced the CL signal 
and others inhibited the reaction. The method was 
simple and sensitive, but these substances need to be 
removed before it could be used for FT4 determina-
tion in blood samples. 
Analysis of serum samples 
Expected ranges of values 
 A study of 70 normal human sera were under-
taken to determine expected values. The results were 
presented in Table 6. It can be seen that the correlation 
coefficient was 0.9988, Ū presenting mean sample 
values was 1.043 ng dL-1, and standard deviation (SD) 
was 0.370. The expected values (Ū+2SD) ranged from 
0.303 ng dL-1 to 1.783 ng dL-1.  
Clinical sample examination  
Serum samples of normal people and hypothy-
roid or hyperthyroid patients collected from 301 Hos-
pital were examined. The results were shown in Table 
7. The positive and negative samples could be distin-
guished well and the coincidence ratios were 98% and 
97.5% for positive and negative samples, respectively. 
Correlation with other methods 
FT4 concentrations in the sera were simultane-
ously determined using the present method, a con-
ventional RIA method and a Bayer ACS-180SE detec-
tion system. Good relationships were obtained as 
shown in Fig. 6a and Fig. 6b, which means this 
method has great potential in the clinical diagnosis. Int. J. Biol. Sci. 2007, 3 
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Table 5. Effects of interfering substances on FT4 determination 
Interfering sub-
stances 
Matrix Triglyceride 
(mmoL L-1) 
Sodium cit-
rate (g L-1) 
Heparin 
(mg L-1)
Hemoglobin 
(μmoL L-1) 
Sodium 
oxalate (g 
L-1) 
EDTANa2 
(g L-1) 
Bilirubin 
(μmoL L-1)
Conc. of Interfering 
Substance 
0 1.0  5.0  40  0.16  1.25  1.25  0.332 
Total determined 
( ng dL-1 ) 
0.90 0.25  1.77  0.94  0.65 0.80  0.75  0.77 
Interfering substance 
determined ( ng 
dL-1 ) 
0 -0.65  0.87  0.04  -0.25  -0.10  -0.15  -0.13 
Table 6. Determination of FT4 in normal serum (ng dL
-1)  
U1 0.75 U11 1.45 U21 0.74 U31 0.76 U41 1.34 U51 1.05 U61 0.81 
U2 0.98 U12 2.06 U22 1.12 U32 0.80 U42 0.60 U52 1.01 U62 0.66 
U3 0.92 U13 1.79 U23 1.77 U33 0.71 U43 1.57 U53 0.70 U63 1.00 
U4 1.60 U14 1.01 U24 0.81 U34 1.34 U44 1.97 U54 0.66 U64 0.84 
U5 0.99 U15 0.87 U25 0.83 U35 0.74 U45 1.24 U55 0.76 U65 0.79 
U6 1.25 U16 1.79 U26 1.34 U36 1.07 U46 0.80 U56 1.47 U66 0.88 
U7 0.71 U17 1.17 U27 0.76 U37 1.01 U47 1.29 U57 0.83 U67 0.86 
U8 0.86 U18 0.84 U28 0.85 U38 0.73 U48 0.80 U58 0.71 U68 0.93 
U9 0.81 U19 1.17 U29 1.02 U39 0.74 U49 0.85 U59 0.63 U69 0.81 
Table 7. Clinical sample examination results 
Hyperthyroid serum 
(n=47) 
Normal serum (n=80)  Hypothyroid serum 
(n=51) 
Positive coinci-
dence ratio (%) 
Negative coincidence ratio 
(%) 
Positive Negative  Positive  Negative  Positive Negative 
47 0 2  78  49 2 
98.0 97.5 
 
 
 
      
Figure 6. Correlation between the proposed method and other methods. (a) Proposed method and RIA method, (b) proposed 
method and Bayer ACS-180SE detection system 
 
 
4.  Conclusions 
 
A highly sensitive and selective microplate 
CLEIA demonstrated for the determination of FT4 in 
serum samples has been developed and optimized. 
The proposed method comprises anti-T4 antibody 
coated microplate, HRP-labeled T4 analog and a CL 
detection system. With the assay, FT4 can be repro-
ducibly detected in human serum at a concentration as 
low as 0.09 ng dL-1. A stable calibration curve was also 
established with the linear correlation coefficient of 
0.9997. Data from the developed method highlights 
the acceptable intra-assay (less than 11%) and in-
ter-assay (less than 16%) precision. In summary, this 
assay provides apparent advantages and shows great 
potential in the clinical diagnosis. Int. J. Biol. Sci. 2007, 3 
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Figure 7. Structures of T4, T3 and rT3 
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